Company news

Black Diamond Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company

December 11, 2022

Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 7, 2022

Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

October 25, 2022

Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 8, 2022

Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference

August 2, 2022

Black Diamond Therapeutics to Present at the Jefferies Global Healthcare Conference

June 5, 2022

Black Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer

May 31, 2022

Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 16, 2022

Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine

May 11, 2022

Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 10, 2022

Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment

April 24, 2022

Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer

April 17, 2022

Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference

April 6, 2022

Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors

April 6, 2022

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

March 16, 2022

Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

March 1, 2022

Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer

February 21, 2022

Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer

January 10, 2022

Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022

January 9, 2022

Black Diamond Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

Black Diamond Therapeutics to Present at Upcoming Investor Conferences

November 7, 2021

Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 7, 2021

Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 7, 2021

Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 29, 2021

Black Diamond Therapeutics to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

September 20, 2021

Black Diamond Therapeutics and OpenEye Scientific Announce Collaboration to Expand MAP Drug Discovery Platform

September 20, 2021

Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 11, 2021

Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors

August 9, 2021

Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations

May 18, 2021

Black Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of MasterKey-01 Clinical Trial

May 16, 2021

Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 6, 2021

Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology

April 27, 2021

Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

April 9, 2021

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

March 24, 2021

Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

March 9, 2021

Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021

March 1, 2021

Black Diamond Therapeutics to Present at the BMO Biopharma Spotlight Series

February 10, 2021

Black Diamond Therapeutics Announces Appointment of Oncology Clinical Development Veteran Dr. Kapil Dhingra to Board of Directors

January 19, 2021

Black Diamond Therapeutics to Present at the J.P. Morgan 39th Annual Healthcare Conference

January 4, 2021

Black Diamond Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

November 23, 2020

Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting

November 19, 2020

Black Diamond Therapeutics to Present at the Jefferies 2020 Virtual London Healthcare Conference

November 10, 2020

Black Diamond Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 9, 2020

Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium

October 25, 2020

Black Diamond Therapeutics to Present Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium

October 11, 2020

Black Diamond Therapeutics Announces the Appointment of Biopharmaceutical Veteran Robert A. Ingram as Chairman of the Board

September 28, 2020

Black Diamond Therapeutics Announces the Appointment of Rachel Humphrey, M.D., as Chief Medical Officer

September 7, 2020

← Newer news releases

Decks

The 5 newest of 7 decks. Every deck is listed under its year.